Business Context and Reporting Period
This Form 8-K is a current report filed by Emerald Bioscience, Inc. (formerly Nemus Bioscience, Inc.) on August 7, 2019. The filing discloses material changes to the Company's manufacturing agreements for its active pharmaceutical ingredients, specifically THCVHS and CBDVHS.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed is an upfront payment of $257,800 associated with a new manufacturing amendment.
Material Changes
- New Agreement: Entered into a First Amendment to the Master Development and Clinical Supply Agreement with Noramco, Inc. to add the manufacture of THCVHS.
- Payment Terms: The Company agreed to pay $257,800 upfront to Noramco, with additional payments due upon the shipping of GMP active pharmaceutical ingredient.
- Termination: Terminated a letter agreement dated July 31, 2018, with Albany Molecular Research, Inc. (AMRI) for the manufacture of THCVHS, effective August 7, 2019.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the agreement changes. The filing notes that certain confidential portions of the attached exhibit were omitted as they are not material but would be competitively harmful if disclosed. No specific forward-looking guidance or risk factors beyond the standard competitive nature of the omitted data are detailed in this report.
Investor Verification Checklist
- Verify the total projected cost of the amended Noramco Agreement beyond the $257,800 upfront payment.
- Confirm the timeline for the first shipment of THCVHS from Noramco to trigger additional payments.
- Assess the impact of terminating the AMRI agreement on the Company's supply chain continuity.
- Review the full text of Exhibit 10.1 for any non-public terms regarding pricing or exclusivity.